Genocea Biosciences

About:

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.

Website: http://www.genocea.com

Twitter/X: GenoceaBio

Top Investors: Alexandria Real Estate Equities, Bill & Melinda Gates Foundation, Polaris Partners, SR One, Lux Capital

Description:

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Total Funding Amount:

$521M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2006-01-01

Contact Email:

website.inquiry(AT)genocea.com

Founders:

Chip Clark, Darren Higgins, David Sinclair, Josh Wolfe, Kevin Bitterman

Number of Employees:

51-100

Last Funding Date:

2020-07-22

IPO Status:

Public

© 2025 bioDAO.ai